Pharmatest Services is part of the NK-ENGAGE project (Novel Synthetic Polypeptides for Natural Killer Cell -mediated Immunotherapy for the Treatment
Your data. DELIVERED.
Full-service preclinical CRO specialized in oncology and skeletal disease models
Are you looking for something special?
PHARMATEST offers preclinical in vitro assays, in vivo efficacy models and ex vivo bone analysis services in the fields of oncology and skeletal diseases.
We are the leading experts in combining cancer and bone biology having special expertise in bone metastases. Our cancer models cover comprehensive portfolio of xenograft, syngeneic and immuno-oncology models. We have substantial experience in performing studies with targeted radionuclide therapy in both, in vitro and in vivo studies.
Our models of skeletal diseases include osteoclast and osteoblast in vitro studies and animal models of osteoporosis, osteoarthritis and rare bone disease.
Ex vivo services cover complete histomorphometry and non-invasive imaging for bone and soft tissue and large panel of biomarkers for preclinical and clinical samples. Via our large collaboration network, we can also offer GLP-toxicology studies for you.
Our services have been developed with just one goal in mind – to make your nonclinical drug development faster and more predictive. Our mission is to offer clinically predictive preclinical models in order to decrease the currently high failure rates in clinical trials.
All studies are performed at modern state-of-the-art research laboratories by our committed specialists with exceptionally strong scientific and technical expertise. Our carefully validated and optimized models have high clinical predictivity to save your time and costs. We utilize our expert knowledge and experience to select the correct model for you or customize solutions specifically to your needs. During the past 20 years, we have served hundreds of clients globally by testing thousands of their compounds.
We are delighted to announce our participation in ASBMR 2023 Annual Meeting. The meeting will take place in Vancouver, Canada
New publication assessing bone health effects of radium-223 combo treatment in prostate cancer bone metastases model
New study assessing bone health effects of radium-223, abiraterone acetate, prednisone, and zoledronic acid combo treatment in prostate cancer bone